JMP Securities Maintains Market Outperform on ACADIA Pharmaceuticals, Raises Price Target to $31
Portfolio Pulse from richadhand@benzinga.com
JMP Securities analyst Jason Butler maintains a Market Outperform rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) and raises the price target from $23 to $31.
June 14, 2023 | 3:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities maintains a Market Outperform rating on ACADIA Pharmaceuticals and raises the price target from $23 to $31.
The news of JMP Securities maintaining a Market Outperform rating and raising the price target for ACADIA Pharmaceuticals is positive for the company's stock. This indicates that the analyst believes the stock will outperform the market and has increased confidence in the company's future performance. This is likely to have a positive impact on the stock price in the short term as investors may view this as a sign of strength and potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100